DTx provides evidence-based treatments utilizing software, such as various mobile health applications, that may be used to supplement or replace conventional treatment method of an illnesses.
Digital Therapeutics: Augmenting patient health outcomes
1. Global Industry Analysis,
Size, Share, Trends,
Analysis, Growth, and
Forecast 2020 - 2030
TMR Research
www.tmrresearch.com
DigitalTherapeutics
(DTx)Market
2. DigitalTherapeutics
(DTx)Market
A greater focus on preventive healthcare, the need to reduce
healthcare costs, more expenditure in digital therapies and
increasing prevalence of avoidable chronic illnesses are all likely to
drive the growth of the global digital therapeutics (DTx) market in
the near future. DTx provides evidence-based treatments utilizing
software, such as various mobile health applications, that may be
used to supplement or replace conventional treatment method of
an illnesses.
TMR Research
www.tmrresearch.com
1MARKET OVERVIEW
3. DigitalTherapeutics
(DTx)Market
Chronic disease's high incidence and prevalence rate is a serious
problem for healthcare systems all over the world. Patients
suffering from chronic illnesses provide a considerable
challenge in terms of therapy, since biopsychic or psychosomatic
variables frequently affect these patients. Patients must modify
their behavior as part of this new self-care culture since chronic
illnesses are typically linked with significant levels of
uncertainties.
2KEY TRENDS
TMR Research
www.tmrresearch.com
4. DigitalTherapeutics
(DTx)Market
North America is one of the prominent regions in the global digital
therapeutics (DTx) market and the region is followed by Europe.
Expansion of the market in North America is fueled by factors such as
changes in the reimbursement system for digital therapeutics,
augmented investments in digital therapeutics, regulatory initiatives to
promote technical breakthroughs, and the entry of new startups.
3REGIONAL ASSESSMENT
TMR Research
www.tmrresearch.com
5. DigitalTherapeutics
(DTx)Market
One of the recent developments in the global digital
therapeutics (DTx) market is mentioned as below
In April 2021, US-based Welldoc Inc. and DexCom, Inc.,
developer of continuous glucose monitoring system, have
teamed up to create a new product. This collaboration
allowed BlueStar to offer Dexcom G6 CGM to individuals
with Type 2 diabetes. This new product serves as a single
platform for better health.
4COMPETITVE ANALYSIS
TMR Research
www.tmrresearch.com